glp 1 for non obese people GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Optimizing GLP-1 therapies for obesity

20.8% of patients reported using Tirzepatide, 15.3% reported utilizing a combination of multiple drugs

It's usually worse in the beginning and gets better over time

Studies show that when magnesium is low, brain cells produce less glutathione, leaving them unprotected against harmful stress and toxins

The combination exists only in theoretical pharmacological analysis and, likely, in unsupervised self-experimentation that produces no publishable data

Limitations, Side Effects and Unanswered Questions Some concerns around GLP-1s, notably insurance approval and out-of-pocket cost, will remain a consideration regardless of intended use